Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$0.72 - $1.66 $8,795 - $20,278
-12,216 Reduced 83.14%
2,478 $4,000
Q4 2023

Feb 06, 2024

SELL
$0.68 - $1.31 $501 - $965
-737 Reduced 4.78%
14,694 $13,000
Q2 2023

Aug 11, 2023

BUY
$1.79 - $4.59 $8,699 - $22,307
4,860 Added 45.97%
15,431 $27,000
Q1 2023

May 02, 2023

SELL
$2.84 - $3.92 $4,092 - $5,648
-1,441 Reduced 12.0%
10,571 $41,000
Q3 2022

Nov 09, 2022

BUY
$4.08 - $5.82 $791 - $1,129
194 Added 1.64%
12,012 $66,000
Q2 2022

Aug 15, 2022

BUY
$4.15 - $8.37 $398 - $803
96 Added 0.82%
11,818 $53,000
Q1 2022

Jun 30, 2022

SELL
$5.91 - $14.38 $5,850 - $14,236
-990 Reduced 7.79%
11,722 $86,000
Q4 2021

Feb 15, 2022

SELL
$5.21 - $8.61 $1,818 - $3,004
-349 Reduced 2.67%
12,712 $82,000
Q3 2021

Oct 29, 2021

SELL
$4.45 - $10.63 $2,380 - $5,687
-535 Reduced 3.93%
13,061 $76,000
Q2 2021

Aug 16, 2021

BUY
$8.11 - $11.11 $28,563 - $39,129
3,522 Added 34.96%
13,596 $140,000
Q1 2021

May 13, 2021

SELL
$9.85 - $17.69 $8,746 - $15,708
-888 Reduced 8.1%
10,074 $106,000
Q4 2020

Feb 12, 2021

BUY
$14.15 - $17.19 $863 - $1,048
61 Added 0.56%
10,962 $169,000
Q3 2020

Oct 30, 2020

SELL
$14.14 - $19.71 $4,623 - $6,445
-327 Reduced 2.91%
10,901 $159,000
Q2 2020

Aug 10, 2020

BUY
$16.6 - $25.25 $10,856 - $16,513
654 Added 6.18%
11,228 $213,000
Q1 2020

May 13, 2020

SELL
$14.38 - $27.72 $4,314 - $8,316
-300 Reduced 2.76%
10,574 $203,000
Q4 2019

Feb 13, 2020

BUY
$9.23 - $19.67 $5,685 - $12,116
616 Added 6.01%
10,874 $208,000
Q3 2019

Nov 13, 2019

SELL
$5.66 - $11.85 $435 - $912
-77 Reduced 0.75%
10,258 $99,000
Q2 2019

Aug 14, 2019

BUY
$4.32 - $6.43 $44,647 - $66,454
10,335 New
10,335 $62,000

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $52.7M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.